ArticleScientific reports2025
Somatic mutations in the TG and RELA genes specific for radioiodine-refractory thyroid cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
Abstract
Radioactive iodine-refractory (RAI-R) thyroid cancer is associated with poor prognosis and limited treatment options. Identifying RAI-R status early in treatment is crucial for optimizing therapy. This study aims to identify genetic variants distinguishing RAI-R from radioiodine-sensitive (RAI-S) thyroid cancers. The study included six RAI-R patients and six age-matched RAI-S controls. DNA from tumor tissues and peripheral leukocytes of RAI-R patients underwent long-read whole-genome sequencing, while tumor DNA from RAI-S patients underwent whole-exome sequencing. RNA and immunohistochemistry (IHC) analyses were performed to assess candidate variants. Among the six RAI-R patients, three showed disease progression. These patients harbored somatic heterozygous variants in the TG gene, including a c.7863-7_7864delTTCTCACinsG variant, an 8,232 bp deletion encompassing exons 33-34, and a missense variant (c.5488 C > T; p.Pro1830Ser). No TG variants were found in RAI-S or non-progressive RAI-R patients. Additionally, one RAI-R patient had a somatic nonsense variant in the RELA gene (c.601 C > T; p.Arg201Ter). qRT-PCR showed lower NIS expression in RAI-R patients with TG or RELA variants, whereas RAI-S patients exhibited higher NIS expression. Somatic TG and RELA variants were identified in RAI-R thyroid cancer. These variants could serve as early biomarkers for identifying RAI-R status, enabling more tailored treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.